Get the Stockscreener App
1.95
2.50%
-0.05
After Hours:
1.98
0.03
+1.54%
Autolus Therapeutics Plc Adr stock is traded at $1.95, with a volume of 1.95M.
It is down -2.50% in the last 24 hours and up +25.81% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$2.00
Open:
$2
24h Volume:
1.95M
Relative Volume:
0.65
Market Cap:
$518.98M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.625
EPS:
-1.2
Net Cash Flow:
$-156.57M
1W Performance:
-2.01%
1M Performance:
+25.81%
6M Performance:
-13.72%
1Y Performance:
-22.62%
1-Day Range:
$1.94
$2.07
1-Week Range:
$1.77
$2.07
52-Week Range:
$1.105
$2.70
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.95 | 532.29M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Free cash flow per share of Autolus Therapeutics Plc Sponsored ADR – FWB:6A3A - TradingView — Track All Markets
Autolus Therapeutics (NASDAQ:AUTL) Price Target Raised to $11.00 at Needham & Company LLC - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade - Defense World
Autolus Therapeutics stock jumps after Needham raises price target By Investing.com - Investing.com South Africa
Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - Finviz
Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
The i-80 Gold Corp (IAUX) had a good session last reading, didn’t it? - uspostnews.com
Autolus Therapeutics’ (AUTL) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Views of Wall Street’s Leading Experts on Autolus Therapeutics plc ADR - setenews.com
Wall Street analysts’ outlook for AlphaVest Acquisition Corp (ATMV) - setenews.com
Check Out Autolus Therapeutics plc ADR (AUTL)’s Trade Data Rather Than the Analysts’ Views - Setenews
Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
Ryan Richardson joins Autolus Therapeutics board of directors - Investing.com
An analyst sees good growth prospects for Autolus Therapeutics plc ADR (AUTL) - Setenews
Taking on analysts’ expectations and winning: EON Resources Inc (EONR) - Setenews
Ready to Jump After Recent Trade: BitMine Immersion Technologies Inc (BMNR) - Setenews
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Taking on analysts’ expectations and winning: enVVeno Medical Corporation (NVNO) - Setenews
Check out these key findings about Streamex Corp (STEX) - Setenews
This trade activity should not be overlooked: ETHZilla Corp (ETHZ) - Setenews
A better buy-in window may exist right now for Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
How does Advanced Biomed Inc (ADVB) change from a tortoise to a hare? - Setenews
A look into Mobile health Network Solutions (MNDR)’s deeper side - Setenews
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Taking on analysts’ expectations and winning: Gelteq Ltd (GELS) - Setenews
Wall Street analysts’ outlook for Amaze Holdings Inc (AMZE) - Setenews
Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Finviz
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ - GlobeNewswire Inc.
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
A new trading data show Ashford Hospitality Trust Inc (AHT) is showing positive returns. - Setenews
Taking on analysts’ expectations and winning: Houston American Energy Corp (HUSA) - Setenews
Does Klotho Neurosciences Inc (KLTO) offer a good opportunity for investors? - Setenews
The time has not yet come to remove your chips from the table: Psyence Biomedical Ltd (PBM) - Setenews
Newsmax Inc (NMAX) can make a big difference with a little luck - Setenews
Check Out Dolly Varden Silver Corp (DVS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Views of Wall Street’s Leading Experts on Viomi Technology Co Ltd ADR - Setenews
Are Smart Investors Making the Right Decision? Empery Digital Inc (EMPD) - Setenews
Wall Street analysts’ outlook for Picard Medical Inc (PMI) - Setenews
Autolus Therapeutics plc ADR (AUTL) is looking forward to a strong quarter - Setenews
Views of Wall Street’s Leading Experts on Twin Vee PowerCats Co - Setenews
This trade activity should not be overlooked: Amaze Holdings Inc (AMZE) - Setenews
Wall Street analysts’ outlook for Cypherpunk Technologies Inc (CYPH) - Setenews
William Blair Issues Pessimistic Forecast for AUTL Earnings - Defense World
There is no doubt that Cycurion Inc (CYCU) ticks all the boxes. - Setenews
Check Out SIGA Technologies Inc (SIGA)’s Trade Data Rather Than the Analysts’ Views - Setenews
How Autolus Therapeutics plc (Common Stock) (6A3A) stock moves on employment data2025 Price Targets & Weekly High Momentum Picks - newser.com
Top investors say Autolus Therapeutics plc ADR (AUTL) ticks everything they need - Setenews
Pony AI Inc. ADR (PONY) can make a big difference with a little luck - Setenews
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):